Physician profile
Dina Ibrahim
NPI 1356752380
$7,535.58
in general payments reported to CMS, 2019-2025
19 companies · $647 in 2025
The $647 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,854 · 2022: $1,097 · 2023: $773 · 2024: $2,165 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,197 · Travel and Lodging: $998 · Long Term Medical Supply Or Device Loan: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.66 |
| Travel and Lodging | $998.14 |
| Long Term Medical Supply Or Device Loan | $389.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $2,566.70 | 2021-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Paragon 28, INC. | $2,052.30 | 2021-2023 | Grappler |
| Seapearl East, INC | $770.83 | 2023-2024 | |
| Arthrex, INC. | $640.30 | 2024 | |
| Stryker Corporation | $569.94 | 2021-2025 | Prostep Mica, Citrefix |
| Zynex Medical, INC. | $173.07 | 2025 | Nexwave |
| Smith+Nephew, INC. | $148.61 | 2022-2025 | Evos, Stravix Pl |
| Paratek Pharmaceuticals, INC. | $114.28 | 2022-2024 | Nuzyra |
| Embody, INC. | $105.81 | 2022 | |
| Cardiovascular Systems INC. | $104.32 | 2022 | |
| Treace Medical Concepts, INC. | $68.73 | 2023-2025 | |
| Kerecis Limited | $61.88 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Convatec INC. | $37.57 | 2023 | |
| Organogenesis INC. | $32.31 | 2021-2022 | |
| Bioventus LLC | $24.52 | 2024 | Durolane |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $22.07 | 2024 | |
| Averitas Pharma INC. | $17.46 | 2024 | Qutenza |
| Abbvie INC. | $14.79 | 2022 | |
| Heraeus Medical, LLC. | $10.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.